Survodutide's Cardiovascular Outcomes Trial: Baseline Patient Profile Revealed
Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
Background
Obesity is a global health crisis, significantly increasing the risk of cardiovascular disease (CVD). New anti-obesity medications, while effective for weight loss, require rigorous assessment of their long-term cardiovascular safety and efficacy. Survodutide is a novel dual GLP-1 and glucagon receptor agonist showing promise in weight management. This paper describes the comprehensive baseline characteristics of participants enrolled in the SYNCHRONIZE Cardiovascular Outcomes Trial (CVOT), setting the stage for evaluating Survodutide's cardiovascular impact.